Gilead Sciences, Inc. (GILD) Stock Overview
NASDAQ · Healthcare · Drug Manufacturers - General
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of…
Source: Yahoo Finance
Sector & Industry
Gilead Sciences, Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry group. It is listed on the NASDAQ exchange.
Gilead Sciences, Inc. at a Glance
| Company | Gilead Sciences, Inc. |
| Ticker | GILD |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $134.28 |
| Market cap | $166.72B |
| P/E ratio (trailing) | 18.27 |
| EPS (trailing) | $7.35 |
| 52-week high | $157.29 |
| 52-week low | $107.75 |
| Dividend yield | 2.44% |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 17,000 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Evaluating pharma pipelines, devices and healthcare economics.
Check Price →A practical framework for judging whether a dividend is safe and worth owning.
Check Price →Top-rated books on building an income portfolio from dividend payers.
Check Price →Frequently Asked Questions
What is Gilead Sciences, Inc.'s P/E ratio?
Gilead Sciences, Inc. (GILD) has a trailing P/E ratio of 18.27 as of our latest data snapshot.
What is Gilead Sciences, Inc.'s market cap?
Gilead Sciences, Inc.'s market capitalisation is $166.72B based on the most recent snapshot.
What is GILD's 52-week range?
Over the past 52 weeks, GILD has traded between $107.75 and $157.29.
Prefer raw numbers at a glance? Browse our reference tables for quick lookups.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Related Healthcare Stocks
Data snapshot: 18 July 2026 (Yahoo Finance) · Page last built: